The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Clinical development of new drug–radiotherapy combinations
Open accessAbstract
The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) includes academia, industry, patient groups and regulatory bodies representatives. In this Consensus Statement, recommendations are provided with the aim of increasing the number of novel drugs being successfully registered in combination with radiotherapy in clinical trials for patients with cancer. In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures include the use of radiotherapy, either as a single modality or combined with other treatments. Radiotherapy can provide enormous benefit to patients with cancer. In the past decade, significant technical advances, such as image-guided radiotherapy, intensity-modulated radiotherapy, stereotactic radiotherapy, and proton therapy enable higher doses of radiotherapy to be delivered to the tumour with significantly lower doses to normal surrounding tissues. However, apart from the combination of traditional cytotoxic chemotherapy with radiotherapy, little progress has been made in identifying and defining optimal targeted therapy and radiotherapy combinations to improve the efficacy of cancer treatment. The National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) formed a Joint Working Group with representatives from academia, industry, patient groups and regulatory bodies to address this lack of progress and to publish recommendations for future clinical research. Herein, we highlight the Working Group's consensus recommendations to increase the number of novel drugs being successfully registered in combination with radiotherapy to improve clinical outcomes for patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Stewart, B. W., & Kleihues, P. (2003) · Cited by 2,386
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Self-citationImmunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112824 · Cited by 2,087
Maas, M., Nelemans, P. J., Valentini, V., Das, P., Rödel, C., Kuo, L.-J., Calvo, F. A., García-Aguilar, J., Glynne-Jones, R., Haustermans, K., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70172-8 · Cited by 1,945
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
Dewan, M. Z., Galloway, A. E., Kawashima, N., Dewyngaert, J. K., Babb, J. S., Formenti, S. C., & Demaria, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0265 · Cited by 1,678
Sjoquist, K. M., Burmeister, B. H., Smithers, B. M., Zalcberg, J. R., Simes, R. J., Barbour, A., & Gebski, V. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70142-5 · Cited by 1,647
Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., Dobbs, H. J., Hopwood, P., Lawton, P. A., Magee, B. J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70386-3 · Cited by 1,470
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Bentzen, S. M., Constine, L. S., Deasy, J. O., Eisbruch, A., Jackson, A., Marks, L. B., Ten Haken, R. K., & Yorke, E. D. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.09.040 · Cited by 1,257
(2016) · Wiley eBooks · doi:10.1002/9781119000822 · Cited by 1,148
Expanding global access to radiotherapy
Atun, R., Jaffray, D. A., Barton, M. B., Bray, F., Baumann, M., Vikram, B., Hanna, T. P., Knaul, F. M., Lievens, Y., Lui, T. Y. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00222-3 · Cited by 1,112
Nordsmark, M., Bentzen, S. M., Rudat, V., Brizel, D., Lartigau, E., Stadler, P., Becker, A., Adam, M., Molls, M., Dunst, J., et al. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.038 · Cited by 953
ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
Fornander, T., Cedermark, B., Mattsson, A., Skoog, L., Theve, T., Askergren, J., Rutqvist, L., Glas, U., Silfverswärd, C., Somell, A., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91141-0 · Cited by 920
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3523 · Cited by 864
Ang, K. K., Zhang, Q., Rosenthal, D. I., Nguyen-Tan, P. F., Sherman, E. J., Weber, R. S., Galvin, J. M., Bonner, J. A., Harris, J., El-Naggar, A. K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5633 · Cited by 838
Peters, L. J., O'Sullivan, B., Giralt, J., Fitzgerald, T. J., Trotti, A., Bernier, J., Bourhis, J., Yuen, K., Fisher, R., & Rischin, D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4498 · Cited by 812
Murine models of pulmonary fibrosis
Moore, B. B., & Hogaboam, C. M. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00313.2007 · Cited by 796
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
Patel, U. B., Taylor, F., Blomqvist, L., George, C., Evans, H., Tekkis, P., Quirke, P., Sebag-Montefiore, D., Moran, B., Heald, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.9068 · Cited by 703
Self-citationRepopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686
Golden, E. B., Chhabra, A., Chachoua, A., Adams, S., Donach, M., Fenton-Kerimian, M., Friedman, K., Ponzo, F., Babb, J. S., Goldberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00054-6 · Cited by 667
The mighty mouse: genetically engineered mouse models in cancer drug development
Sharpless, N. E., & DePinho, R. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2110 · Cited by 661
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Douglas, B. G., & Fowler, J. F. (1976) · Radiation Research · doi:10.2307/3574407 · Cited by 604
Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
Cheung, Y. K., & Chappell, R. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.01177.x · Cited by 545
(1981) · The Lancet · doi:10.1016/s0140-6736(81)91281-2 · Cited by 544
Stereotactic body radiotherapy for oligometastases
Tree, A. C., Khoo, V. S., Eeles, R. A., Ahmed, M., Dearnaley, D. P., Hawkins, M. A., Huddart, R. A., Nutting, C. M., Ostler, P. J., & van As, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70510-7 · Cited by 524
Self-citationDose‐Finding Based on Efficacy–Toxicity Trade‐Offs
Thall, P. F., & Cook, J. D. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00218.x · Cited by 522
Radiation and the microenvironment – tumorigenesis and therapy
Barcellos-Hoff, M. H., Park, C., & Wright, E. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1735 · Cited by 513
Berger, A. C., Farma, J., Scott, W. J., Freedman, G., Weiner, L., Cheng, J. D., Wang, H., & Goldberg, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.017 · Cited by 505
Consequential late effects in normal tissues
Dörr, W., & Hendry, J. H. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00429-7 · Cited by 447
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 443
(2020) · Elsevier eBooks · doi:10.1016/c2015-0-05400-4 · Cited by 437
Quantitative Methods for Assessing Drug Synergism
Tallarida, R. J. (2011) · Genes & Cancer · doi:10.1177/1947601912440575 · Cited by 378
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp177 · Cited by 349
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., Roberts, C., & Jayson, G. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.2 · Cited by 348
Self-citationLalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71021-6 · Cited by 342
Dearnaley, D., Syndikus, I., Sumo, G., Bidmead, M., Bloomfield, D., Clark, C., Gao, A., Hassan, S., Horwich, A., Huddart, R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70293-5 · Cited by 308
Self-citationVergis, R., Corbishley, C. M., Norman, A. R., Bartlett, J., Jhavar, S., Borre, M., Heeboll, S., Horwich, A., Huddart, R., Khoo, V., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70076-7 · Cited by 282
Envisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281
Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine
Redig, A. J., & Jänne, P. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.8433 · Cited by 278
Role of Radiation Therapy in Palliative Care of the Patient With Cancer
Lutz, S. T., Jones, J., & Chow, E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1143 · Cited by 263
Swisher, S. G., Erasmus, J., Maish, M., Correa, A. M., Macapinlac, H., Ajani, J. A., Cox, J. D., Komaki, R. R., Hong, D., Lee, H. K., et al. (2004) · Cancer · doi:10.1002/cncr.20585 · Cited by 262
Harrington, K. J., Hingorani, M., Tanay, M. A., Hickey, J., Bhide, S. A., Clarke, P. M., Renouf, L. C., Thway, K., Sibtain, A., McNeish, I. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0196 · Cited by 259
Self-citationSharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors
Taichman, D. B., Backus, J., Baethge, C., Bauchner, H., de Leeuw, P. W., Drazen, J. M., Fletcher, J., Frizelle, F. A., Groves, T., Haileamlak, A., et al. (2016) · JAMA · doi:10.1001/jama.2015.18164 · Cited by 254
Patient-reported outcomes in the evaluation of toxicity of anticancer treatments
Di Maio, M., Basch, E., Bryce, J., & Perrone, F. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.222 · Cited by 251
Mauguen, A., Pignon, J.-P., Burdett, S., Domerg, C., Fisher, D., Paulus, R., Mandrekar, S. J., Belani, C. P., Shepherd, F. A., Eisen, T., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70158-x · Cited by 246
Combinations of Immunotherapy and Radiation in Cancer Therapy
Vatner, R. E., Cooper, B. T., Vanpouille-Box, C., Demaria, S., & Formenti, S. C. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00325 · Cited by 240
Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor
Hiltermann, T. J. N., Pore, M. M., van den Berg, A., Timens, W., Boezen, H. M., Liesker, J. J. W., Schouwink, J. H., Wijnands, W. J. A., Kerner, G. S. M. A., Kruyt, F. A. E., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds138 · Cited by 224
Research Activity and the Association with Mortality
Ozdemir, B. A., Karthikesalingam, A., Sinha, S., Poloniecki, J. D., Hinchliffe, R. J., Thompson, M. M., Gower, J. D., Boaz, A., & Holt, P. J. E. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118253 · Cited by 220
Ringborg, U., Bergqvist, D., Brorsson, B., Cavallin-ståhl, E., Ceberg, J., Einhorn, N., Frödin, J.-E., Järhult, J., Lamnevik, G., Lindholm, C., et al. (2003) · Acta Oncologica · doi:10.1080/02841860310010826 · Cited by 208
Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Ding, N.-H., Li, J., & Sun, L.-Q. (2013) · Current Drug Targets · doi:10.2174/13894501113149990198 · Cited by 206
Bystander effects and radiotherapy
Marín, A., Martín, M., Liñán, O., Alvarenga, F., López, M., Fernández, L., Büchser, D., & Cerezo, L. (2015) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2014.08.004 · Cited by 197
Shah, G. D., Kesari, S., Xu, R., Batchelor, T. T., O'Neill, A. M., Hochberg, F. H., Levy, B., Bradshaw, J., & Wen, P. Y. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000529 · Cited by 195
Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma
Machtay, M., Paulus, R., Moughan, J., Komaki, R., Bradley, J. E., Choy, H., Albain, K., Movsas, B., Sause, W. T., & Curran, W. J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182429682 · Cited by 192
Sharing Clinical Trial Data — A Proposal from the International Committee of Medical Journal Editors
Taichman, D. B., Backus, J., Baethge, C., Bauchner, H., de Leeuw, P. W., Drazen, J. M., Fletcher, J., Frizelle, F. A., Groves, T., Haileamlak, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejme1515172 · Cited by 190
West, C., Davidson, S., Roberts, S., & Hunter, R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.434 · Cited by 185
Machtay, M., Duan, F., Siegel, B. A., Snyder, B. S., Gorelick, J. J., Reddin, J. S., Munden, R., Johnson, D. W., Wilf, L. H., DeNittis, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.5947 · Cited by 175
Role of Type II Pneumocyte Senescence in Radiation-Induced Lung Fibrosis
Citrin, D. E., Shankavaram, U., Horton, J. A., Shield, W., Zhao, S., Asano, H., White, A., Sowers, A., Thetford, A., & Chung, E. J. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt212 · Cited by 174
Tzeng, C.-W. D., Balachandran, A., Ahmad, M., Lee, J. E., Krishnan, S., Wang, H., Crane, C. H., Wolff, R. A., Varadhachary, G. R., Pisters, P. W. T., et al. (2014) · HPB · doi:10.1111/hpb.12154 · Cited by 173
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers
Harrington, K. J., Billingham, L. J., Brunner, T. B., Burnet, N. G., Chan, C. S., Hoskin, P., Mackay, R. I., Maughan, T. S., Macdougall, J., McKenna, W. G., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.240 · Cited by 170
Self-citationMichiels, S., Le Maître, A., Buyse, M., Burzykowski, T., Maillard, E., Bogaerts, J., Vermorken, J. B., Budach, W., Pajak, T. F., Ang, K. K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70023-3 · Cited by 170
Microenvironment and Radiation Therapy
Yoshimura, M., Itasaka, S., Harada, H., & Hiraoka, M. (2012) · BioMed Research International · doi:10.1155/2013/685308 · Cited by 163
Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling
Qayum, N., Muschel, R. J., Im, J. H., Balathasan, L., Koch, C. J., Patel, S. K., McKenna, W. G., & Bernhard, E. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0657 · Cited by 151
Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?
Postel-Vinay, S. C., Gomez‐Roca, C., Molife, L. R., Anghan, B., Lévy, A., Judson, I. R., Bono, J. S. D., Soria, J., Kaye, S. B., & Paolettí, X. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9236 · Cited by 146
The Tumor-Immune Microenvironment and Response to Radiation Therapy
Shiao, S. L., & Coussens, L. M. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9194-9 · Cited by 138
Jain, R. K., Lee, J. J., Hong, D. S., Markman, M., Gong, J., Naing, A., Wheler, J. J., & Kurzrock, R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2684 · Cited by 134
Tumor Response and Survival Predicted by Post-Therapy FDG-PET/CT in Anal Cancer
Schwarz, J. K., Siegel, B. A., Dehdashti, F., Myerson, R. J., Fleshman, J. W., & Grigsby, P. W. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.09.005 · Cited by 130
Peeters, S. G. J. A., Zegers, C. M. L., Biemans, R., Lieuwes, N. G., van Stiphout, R. G. P. M., Yaromina, A., Sun, J. D., Hart, C. P., Windhorst, A. D., van Elmpt, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0018 · Cited by 120
Hentschel, M., Appold, S., Schreiber, A., Abolmaali, N., Abramyuk, A. M., Dörr, W., Kotzerke, J., Baumann, M. A., & Zöphel, K. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1759-3 · Cited by 113
Douglas, B. G., & Fowler, J. F. (2012) · Radiation Research · doi:10.1667/rrav10.1 · Cited by 110
Radiobiological considerations in the design of clinical trials
Bentzen, S. M. (1994) · Radiotherapy and Oncology · doi:10.1016/0167-8140(94)90443-x · Cited by 109
The Hallmarks of Cancer and the Radiation Oncologist: Updating the 5Rs of Radiobiology
Good, J., & Harrington, K. J. (2013) · Clinical Oncology · doi:10.1016/j.clon.2013.06.009 · Cited by 102
Self-citation18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis
Xie, P., Li, M., Zhao, H., Sun, X., Fu, Z., & Yu, J. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0972-y · Cited by 101
Mayr, N. A., Wang, J. Z., Zhang, D., Grecula, J. C., Lo, S. S.-M., Jaroura, D., Montebello, J. F., Zhang, H., Li, K., Lu, L., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.084 · Cited by 91
Randomized Phase II Trial Designs With Biomarkers
Freidlin, B., McShane, L. M., Polley, M. C., & Korn, E. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3946 · Cited by 89
A product of independent beta probabilities dose escalation design for dual‐agent phase I trials
Mander, A., & Sweeting, M. J. (2015) · Statistics in Medicine · doi:10.1002/sim.6434 · Cited by 87
Radiotherapy for Bladder Cancer
Milosevic, M., Gospodarowicz, M. K., Zietman, A. L., Abbas, F., Haustermans, K. M., Moonen, L. M. F., Rödel, C. M., Schoenberg, M., & Shipley, W. U. (2007) · Urology · doi:10.1016/j.urology.2006.05.060 · Cited by 85
Glynne‐Jones, R., Dunst, J., & Sebag‐Montefiore, D. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj052 · Cited by 85
Self-citationEffective Incorporation of Biomarkers into Phase II Trials
McShane, L. M., Hunsberger, S., & Adjei, A. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2033 · Cited by 84
D'Amico, A. V., Chen, M., de Castro, M., Loffredo, M. J., Lamb, D. S., Steigler, A., Kantoff, P. W., & Denham, J. W. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70295-9 · Cited by 83
Radiotherapy and cellular signalling
Lewanski, C. R., & Gullick, W. J. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00391-0 · Cited by 79
Bentzen, S. M., Parliament, M. B., Deasy, J. O., Dicker, A. P., Curran, W. J., Williams, J. P., & Rosenstein, B. S. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.08.076 · Cited by 76
van Baardwijk, A. A. W., Reymen, B. J. T., Wanders, S. L., Borger, J. H., Öllers, M., Dingemans, A. C., Bootsma, G. P., Geraedts, W. H., Pitz, C. C. M., Lunde, R., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.014 · Cited by 74
Lawrence, Y. R., Vikram, B., Dignam, J. J., Chakravarti, A., Machtay, M. X., Freidlin, B., Takebe, N., Curran, W. J., Bentzen, S. M., Okunieff, P. G., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs472 · Cited by 74
Radiation therapy quality assurance in clinical trials – Global harmonisation group
Melidis, C., Bosch, W. R., Iżewska, J., Fidarova, E. F., Zubizarreta, E., Ishikura, S., Followill, D. S., Galvin, J. M., Xiao, Y., Ebert, M. A., et al. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.03.023 · Cited by 70
Radioprotection of normal tissue cells
Maier, P. J., Wenz, F. K., & Herskind, C. (2014) · Strahlentherapie und Onkologie · doi:10.1007/s00066-014-0637-x · Cited by 67
Skin sensitization by misonidazole: A demonstration of uniform mild hypoxia
Stewart, F. A., Denekamp, J., & Randhawa, V. S. (1982) · British Journal of Cancer · doi:10.1038/bjc.1982.139 · Cited by 65
Potential and limitations of bacterial-mediated cancer therapy
Mengesha, A., Dubois, L., Chiu, R. K., Paesmans, K., Wouters, B. G., Lambin, P., & Theys, J. (2007) · Frontiers in bioscience · doi:10.2741/2357 · Cited by 59
Desai, S. P., Ben‐Josef, E., Normolle, D. P., Francis, I. R., Greenson, J. K., Simeone, D. M., Chang, A. E., Colletti, L. M., Lawrence, T. S., & Zalupski, M. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0592 · Cited by 55
Bystander Signalling: Exploring Clinical Relevance Through New Approaches and New Models
Butterworth, K. T., McMahon, S. J., Hounsell, A. R., O’Sullivan, J. M., & Prise, K. M. (2013) · Clinical Oncology · doi:10.1016/j.clon.2013.06.005 · Cited by 54
Radiotherapy and the Tumor Microenvironment: Mutual Influence and Clinical Implications
Thompson, R. F., & Maity, A. M. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_7 · Cited by 53
Zindler, J. D., Thomas, C. R., Hahn, S. M., Hoffmann, A. L., Troost, E. G. C., & Lambin, P. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv305 · Cited by 52
Ruysscher, D. D., van Baardwijk, A. A. W., Steevens, J., Botterweck, A. A. M., Bosmans, G., Reymen, B. J. T., Wanders, R., Borger, J. H., Dingemans, A. C., Bootsma, G. P., et al. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.10.010 · Cited by 48
Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial
Ray, M. E., Bae, K., Hussain, M., Hanks, G. E., Shipley, W. U., & Sandler, H. M. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn489 · Cited by 41
Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer
Hill, E. J., Roberts, C., Franklin, J. M., Enescu, M., West, N. P., MacGregor, T. P., Chu, K.-Y., Boyle, L., Blesing, C., Wang, L.-M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1489 · Cited by 37
Self-citationDíez, P., Vogelius, I. R., & Bentzen, S. M. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.013 · Cited by 36
Hanna, T. P., Shafiq, J., Delaney, G. P., & Barton, M. B. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.02.005 · Cited by 27
A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer
Nieder, C., Pawinski, A., Dalhaug, A., et al. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-3 · Cited by 24
Methods of joint evaluation of efficacy and toxicity in phase II clinical trials
Tournoux, C., Rycke, Y. D., Médioni, J., & Asselain, B. J. R. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2007.01.008 · Cited by 23
Ippolito, E., Massaccesi, M., Digesù, C., Deodato, F., Macchia, G., Pirozzi, G., Cilla, S., Cuscunà, D., Lallo, A. D., Mattiucci, G. C., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.12.046 · Cited by 21
High-Resolution In Vivo Imaging of Fluorescent Proteins Using Window Chamber Models
Palmer, G. M., Fontanella, A. N., Shan, S., & Dewhirst, M. W. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-797-2_3 · Cited by 17
Illidge, T. (2015) · Clinical Oncology · doi:10.1016/j.clon.2015.09.001 · Cited by 15
Self-citation
Cited by
De Ruysscher, D., Niedermann, G., Burnet, N. G., Siva, S., Lee, A. W. M., & Hegi-Johnson, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0064-5 · Cited by 868
Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria
Dharmaraja, A. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01243 · Cited by 582
Molecular mechanisms of tumor resistance to radiotherapy
Wu, Y., Song, Y., Wang, R., & Wang, T. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01801-2 · Cited by 527
Exosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
Park, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C. (2019) · Theranostics · doi:10.7150/thno.37198 · Cited by 382
Metadata
- Authors
- on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., Billingham, L., Brown, S. R., Buckland, S., Bulbeck, H., Chalmers, A. J., Clack, G., Cranston, A. N., Damstrup, L., Ferraldeschi, R., Forster, M. D., Golec, J., Hagan, R. M., Hall, E., Hanauske, A.-R., Harrington, K. J., Haswell, T., Hawkins, M. A., Illidge, T., Jones, H., Kennedy, A. S., McDonald, F., Melcher, T., O'Connor, J. P. B., Pollard, J. R., Saunders, M. P., Sebag-Montefiore, D., Smitt, M., Staffurth, J., Stratford, I. J., & Wedge, S. R.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2016-06-01
- Volume
- 13
- Issue
- 10
- Pages
- 627-642
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2415000849
- Cited by
- 320
- References
- 114
- FWCI
- 4.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.